ATEC — Alphatec Holdings, Inc. stock price, charts and financials

Latest market price

9.32

+0.01+0.14%

Overview Short InterestFilings

ATECQT40Alphatec Holdings, Inc.·NASDAQ

Overview Short InterestFilings

9.32+0.14%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CNMD+1.34%$49.78 IART+0.20%$17.29 ENOV-5.77%$25.07 TNDM-0.07%$22.36 AORT-1.92%$26.60 IRMD-0.89%$91.67 INSP+0.92%$60.72 AVNS+0.04%$24.99

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.83	Insider Own	-	Shs Outstand	153.79M	Perf Week	-2.21%

Market Cap	1.43B	Forward P/E	15.63	EPS next Y	0.60	Insider Trans	-0.75%	Shs Float	121.05M	Perf Month	-2.10%

Enterprise Value	1.92B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	11.36%	Perf Quarter	20.13%

Income	-108.96M	P/S	1.76	EPS this Y	138.82%	Inst Trans	-	Short Ratio	3.88	Perf Half Y	-31.04%

Sales	815.04M	P/B	-	EPS next Y	84.83%	ROA	-13.91%	Short Interest	13.75M	Perf YTD	-55.75%

Book/sh	-	P/C	25.01	EPS next 5Y	49.04%	ROE	-818.99%	52W High	23.32 -60.03%	Perf Year	-38.75%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-7.24%	52W Low	6.83 36.51%	Perf 3Y	-45.68%

Dividend Est.	-	EV/EBITDA	142.47	Sales past 3/5Y	29.60% 39.43%	Gross Margin	66.15%	Volatility	5.57% 4.59%	Perf 5Y	-36.84%

Dividend TTM	-	EV/Sales	2.35	EPS Y/Y TTM	26.55%	Oper. Margin	-5.55%	ATR (14)	0.52	Perf 10Y	104.22%

Dividend Ex-Date	-	Quick Ratio	1.07	Sales Y/Y TTM	28.76%	Profit Margin	-13.50%	RSI (14)	51.97	Recom	2.20

Dividend Gr. 3/5Y	-	Current Ratio	1.89	EPS Q/Q	4.35%	SMA20	2.27%	Beta	0.83	Target Price	16.22

Payout	0.00%	Debt/Eq	-	Sales Q/Q	13.61%	SMA50	6.38%	Rel Volume	0.79	Prev Close	9.31

Employees	913	LT Debt/Eq	15.25	Earnings	Oct 29	SMA200	-30.75%	Avg Volume	2.93M	Price	9.32

IPO Date	Jun 01, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-899.00% -2.74%	Net Debt/EBITDA	36.07	Volume	2,327,106	Change	0.14%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-05-26	Reiterated	UBS	Buy	$15 → $16
Aug-05-26	Reiterated	BMO Capital	Outperform	$11 → $12
Jul-28-26	Initiated	UBS	Buy	$15
Jul-23-26	Initiated	Stephens	Overweight	$15
Jul-08-26	Initiated	BMO Capital	Outperform	$11
Jul-08-26	Reiterated	Stifel Nicolaus		$20 → $13
May-06-26	Reiterated	Lake Street	Buy	$25 → $15
May-06-26	Reiterated	Needham	Buy	$23 → $14
May-06-26	Reiterated	Piper Sandler	Overweight	$25 → $14
May-06-26	Reiterated	Canaccord Genuity	Buy	$25 → $23

Latest News

Aug-04-26

Aug-04-2610:30PM

Alphatec Holdings, Inc. (ATEC) Q2 2026 Earnings Call Transcriptseekingalpha.com

08:02PM

Alphatec (ATEC) Q2 Earnings Lag Estimateszacks.com

06:04PM

Alphatec Q2 Earnings Call Highlightsmarketbeat.com

04:09PM

Alphatec Holdings Sees FY2026 Sales $882.000M vs $882.413M EstBenzinga

04:05PM

ATEC Reports Second Quarter Financial Resultsbusinesswire.com

Jul-28-26

Jul-28-2602:45PM

UBS Initiates Coverage On Alphatec Holdings with Buy Rating, Announces Price Target of $15Benzinga

Jul-27-26

Jul-27-2604:35PM

ATEC Announces Participation in Upcoming Investor Conferencesbusinesswire.com

Jul-23-26

Jul-23-2602:48PM

Stephens & Co. Initiates Coverage On Alphatec Holdings with Overweight Rating, Announces Price Target of $15Benzinga

Jul-15-26

Jul-15-2604:35PM

ATEC to Report Second Quarter 2026 Financial Results on August 4, 2026businesswire.com

Jul-09-26

Jul-09-2610:30AM

BMO Capital Initiates Coverage On Alphatec Holdings with Outperform Rating, Announces Price Target of $11Benzinga

Jul-08-26

Jul-08-2609:16AM

Stifel Maintains Buy on Alphatec Holdings, Lowers Price Target to $13Benzinga

Jul-07-26

Jul-07-2608:31AM

Alphatec Holdings Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholdersglobenewswire.com

Company

Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/30/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	816	764	612	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	276	232	187	—	—	—	—	—	—
Gross Profit	538	532	424	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	508	499	450	—	—	—	—	—	—
Research and Development	78	76	81	—	—	—	—	—	—
Other Operating Expense	-2	39	29	—	—	—	—	—	—
Operating Income	-45	-82	-136	—	—	—	—	—	—
Interest Expense	41	21	25	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-24	-40	-1	—	—	—	—	—	—
Net Income Before Taxes	-111	-143	-162	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-111	-143	-162	—	—	—	—	—	—
Net Income From Continuing Operations	-111	-143	-162	—	—	—	—	—	—
Net Income	-111	-143	-162	—	—	—	—	—	—
EPS (Recurring)	-0.72	-0.96	-1.13	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.72	-0.96	-1.13	—	—	—	—	—	—
EPS (Diluted)	-0.72	-0.96	-1.13	—	—	—	—	—	—
EBITDA	13	-40	-54	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	1.77	4.13	2.15	—	—	—	—	—	—
Gross Margin	65.93	69.63	69.28	—	—	—	—	—	—
Operating Margin	-5.51	-10.73	-22.22	—	—	—	—	—	—
Net Margin	-13.60	-18.72	-26.47	—	—	—	—	—	—
Shares Outstanding	155	150	143	—	—	—	—	—	—
Market Capitalization	1,445	3,156	1,313	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Marshall Tyson Eliot	GENERAL COUNSEL & CORP. SEC.	Aug 05 '26	Sale	9.65	8,168	78,821	630,398	Aug 07
MCGINNIS KAREN K	Director	Jun 11 '26	Sale	8.01	6,050	48,461	94,671	Jun 12
Valentine Keith	Director	May 11 '26	Buy	7.00	35,000	245,000	232,271	May 11
Valentine Keith	Director	May 08 '26	Buy	7.54	43,847	330,606	197,271	May 11
Valentine Keith	Director	May 07 '26	Buy	7.49	56,153	420,586	153,424	May 11
Marshall Tyson Eliot	GENERAL COUNSEL & CORP. SEC.	Apr 07 '26	Option Exercise	2.52	102,500	258,050	661,959	Apr 09
Lish Scott	CHIEF OPERATING OFFICER	Mar 13 '26	Sale	12.30	260,535	3,204,581	815,704	Mar 17
Koning John Todd	CHIEF FINANCIAL OFFICER	Mar 13 '26	Sale	12.36	79,789	986,192	600,721	Mar 17
Sponsel David	EVP, SALES	Mar 11 '26	Sale	12.52	163,452	2,046,419	504,932	Mar 13
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Mar 09 '26	Sale	12.45	82,765	1,030,424	1,726,209	Mar 10
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Mar 06 '26	Sale	12.22	33,602	410,616	1,808,974	Mar 10
Marshall Tyson Eliot	GENERAL COUNSEL & CORP. SEC.	Mar 05 '26	Sale	12.49	88,835	1,109,549	559,459	Mar 09
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Feb 12 '26	Option Exercise	2.14	251,176	538,501	1,424,201	Feb 17
Sponsel David	EVP, SALES	Feb 05 '26	Sale	13.79	60,425	833,261	349,500	Feb 06
Hunsaker Craig E	EVP, PEOPLE & CULTURE	Feb 03 '26	Sale	14.71	37,358	549,536	1,173,025	Feb 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.